James R Berenson

Summary

Affiliation: Institute for Myeloma and Bone Cancer Research
Country: USA

Publications

  1. ncbi request reprint Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
    James R Berenson
    Institute for Myeloma Bone Cancer Research, West Hollywood, California 90069, USA
    Cancer 104:2141-8. 2005
  2. doi request reprint Hematology: Bortezomib in newly diagnosed multiple myeloma
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA
    Nat Rev Clin Oncol 6:255-6. 2009
  3. ncbi request reprint Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma
    James R Berenson
    Oncotherapeutics Inc, West Hollywood, CA, USA
    J Clin Oncol 24:937-44. 2006
  4. ncbi request reprint Myeloma bone disease
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, 9201 W Sunset Blvd, Suite 300, W Hollywood, CA 90069, USA
    Best Pract Res Clin Haematol 18:653-72. 2005
  5. ncbi request reprint Recommendations for zoledronic acid treatment of patients with bone metastases
    James R Berenson
    Monteray Zoledronic Acidf Advisory Board, Institute for Myeloma and Bone Cancer Research, 9201 W Sunset Boulevard, Suite 300, West Hollywood, California 90069, USA
    Oncologist 10:52-62. 2005
  6. doi request reprint Vorinostat enhances the antimyeloma effects of melphalan and bortezomib
    Richard A Campbell
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, USA
    Eur J Haematol 84:201-11. 2010
  7. ncbi request reprint Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid
    Richard A Campbell
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA
    Br J Haematol 138:467-78. 2007
  8. doi request reprint The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
    Eric Sanchez
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, USA
    Leuk Res 35:373-9. 2011
  9. doi request reprint The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan
    Eric Sanchez
    Institute for Myeloma and Bone Cancer Research, 9201 W Sunset Boulevard, West Hollywood, CA 90069, USA
    Br J Haematol 148:569-81. 2010
  10. doi request reprint Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA
    Ann Hematol 87:623-31. 2008

Detail Information

Publications69

  1. ncbi request reprint Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
    James R Berenson
    Institute for Myeloma Bone Cancer Research, West Hollywood, California 90069, USA
    Cancer 104:2141-8. 2005
    ..Bortezomib, a first-in-class proteasome inhibitor, is active with manageable toxicities in relapsed and/or refractory myeloma...
  2. doi request reprint Hematology: Bortezomib in newly diagnosed multiple myeloma
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA
    Nat Rev Clin Oncol 6:255-6. 2009
    ..A randomized trial has established that bortezomib not only improves response rates but also prolongs the lives of patients with multiple myeloma who are not candidates for high-dose chemotherapy...
  3. ncbi request reprint Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma
    James R Berenson
    Oncotherapeutics Inc, West Hollywood, CA, USA
    J Clin Oncol 24:937-44. 2006
    ..Bortezomib has shown synergy with melphalan in preclinical models. We assessed the safety, tolerability, and response rate in a dose-escalation study of this combination for relapsed or refractory multiple myeloma patients...
  4. ncbi request reprint Myeloma bone disease
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, 9201 W Sunset Blvd, Suite 300, W Hollywood, CA 90069, USA
    Best Pract Res Clin Haematol 18:653-72. 2005
    ..A number of other types of new anti-bone-resorptive agents are also in early clinical development...
  5. ncbi request reprint Recommendations for zoledronic acid treatment of patients with bone metastases
    James R Berenson
    Monteray Zoledronic Acidf Advisory Board, Institute for Myeloma and Bone Cancer Research, 9201 W Sunset Boulevard, Suite 300, West Hollywood, California 90069, USA
    Oncologist 10:52-62. 2005
    ..With these simple precautions, intravenous bisphosphonate therapy is safe for long-term use and provides durable treatment benefits...
  6. doi request reprint Vorinostat enhances the antimyeloma effects of melphalan and bortezomib
    Richard A Campbell
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, USA
    Eur J Haematol 84:201-11. 2010
    ..Examine the antitumor activity of the histone deacetylase inhibitor vorinostat's antitumor activity against multiple myeloma (MM) using cell lines and a murine xenograft model...
  7. ncbi request reprint Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid
    Richard A Campbell
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA
    Br J Haematol 138:467-78. 2007
    ..These in vitro and in vivo results suggest that addition of ATO to other antimyeloma agents may result in improved outcomes for patients with relapsed or refractory MM...
  8. doi request reprint The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
    Eric Sanchez
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, USA
    Leuk Res 35:373-9. 2011
    ..LBH589 with melphalan or doxorubicin also showed significantly enhanced anti-myeloma activity in vivo. These findings provide the basis for clinical development of these combination therapies...
  9. doi request reprint The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan
    Eric Sanchez
    Institute for Myeloma and Bone Cancer Research, 9201 W Sunset Boulevard, West Hollywood, CA 90069, USA
    Br J Haematol 148:569-81. 2010
    ..These studies provide strong preclinical rationale for further development of this novel PI in the treatment of MM as a monotherapy as well as combined with either melphalan or bortezomib...
  10. doi request reprint Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA
    Ann Hematol 87:623-31. 2008
    ..In conclusion, bortezomib plus melphalan is a steroid- and immunomodulatory drug-free regimen that may provide a treatment alternative for elderly patients and patients with significant comorbidity...
  11. ncbi request reprint A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma
    James R Berenson
    Institute for Myeloma and Bone Cancer Research and Oncotherapeutics Inc, West Hollywood, CA 90069, USA
    Clin Cancer Res 13:1762-8. 2007
    ....
  12. doi request reprint A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients
    James R Berenson
    Oncotherapeutics, James R Berenson, MD, Inc Institute for Myeloma and Bone Cancer Research, 9201 W Sunset Blvd, West Hollywood, CA 90069, USA
    Br J Haematol 155:580-7. 2011
    ..This modified regimen of dexamethasone, bortezomib and PLD shows improved tolerability and safety while maintaining a high response rate when compared to standard treatment with these agents in the frontline setting...
  13. doi request reprint Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
    Eric Sanchez
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA
    Br J Haematol 158:727-38. 2012
    ..These results suggest that serum BCMA levels may be a new biomarker for monitoring disease status and overall survival of MM patients...
  14. doi request reprint A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma
    James R Berenson
    Oncotherapeutics, Los Angeles, CA, USA
    Ann Hematol 93:89-98. 2014
    ..Panobinostat + melphalan appears to have tolerability issues in a dosing regimen capable of producing a response. Care must be taken to balance tolerability and efficacy with this combination...
  15. doi request reprint CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma
    Eric Sanchez
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA
    Leuk Res 36:1422-7. 2012
    ..The favorable results obtained from the three xenograft studies suggest that delanzomib in combination with dexamethasone and lenalidomide should be explored for the treatment of MM...
  16. doi request reprint Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen
    James R Berenson
    Oncotherapeutics, Los Angeles, CA, USA
    Eur J Haematol 82:433-9. 2009
    ..We conducted a single-arm, multicentre phase 2 study to evaluate bortezomib, ascorbic acid and melphalan (BAM) for patients with newly diagnosed multiple myeloma (MM)...
  17. ncbi request reprint Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth
    Haiming Chen
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA
    Blood 110:287-95. 2007
    ..Because the expression of this protein is very limited in normal adult tissues, PTN may represent a new target for the treatment of MM...
  18. doi request reprint Anti-myeloma effects of the novel anthracycline derivative INNO-206
    Eric Sanchez
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA
    Clin Cancer Res 18:3856-67. 2012
    ..Because INNO-206 has not been previously evaluated in any hematologic malignancy, we determined its anti-multiple myeloma effects...
  19. doi request reprint A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma
    Gabriel N Waterman
    James R Berenson, M D, Inc, West Hollywood, CA, USA
    Ann Hematol 90:193-200. 2011
    ..One patient discontinued this regimen due to an adverse event (grade II PN). DVD appears to represent a well-tolerated regimen with a high response rate for the treatment of R/R MM patients...
  20. doi request reprint A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA
    Clin Cancer Res 15:1069-75. 2009
    ..This open-label, phase I dose-escalation study assessed the safety, tolerability, and initial efficacy of Samariam 153 (153Sm)-lexidronam/bortezomib combination therapy for patients with relapsed/refractory multiple myeloma...
  21. pmc Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis
    Haiming Chen
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA
    Blood 113:1992-2002. 2009
    ..Our results suggest that vasculogenesis in human MM may develop from tumoral production of PTN, which orchestrates the transdifferentiation of monocytes into VECs...
  22. doi request reprint Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma
    James R Berenson
    Oncotherapeutics, Institute for Myeloma and Bone Cancer Research, 9201 W Sunset Blvd, West Hollywood, CA 90069, USA
    Br J Haematol 160:321-30. 2013
    ..Bendamustine plus bortezomib was well tolerated with promising efficacy in this heavily pretreated population...
  23. ncbi request reprint Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA
    Br J Haematol 135:174-83. 2006
    ..This steroid-free regimen was effective and well tolerated in this heavily pretreated group. These results indicate that the MAC regimen is a new therapeutic option for patients with relapsed or refractory MM...
  24. doi request reprint Multiple myeloma: improved outcomes with new therapeutic approaches
    Shahrooz Eshaghian
    Institute for Myeloma and Bone Cancer Research, West Hollywood, California, USA
    Curr Opin Support Palliat Care 6:330-6. 2012
    ..This review highlights the newest approaches with already approved drugs for treating this common B-cell malignancy...
  25. doi request reprint Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss
    James R Berenson
    Oncotherapeutics, Institute for Myeloma and Bone Cancer Research, James R Berenson, M D, Inc, 9201 West Sunset Boulevard, West Hollywood, CA 90069, USA
    Clin Cancer Res 14:6289-95. 2008
    ..This study was undertaken to determine the efficacy and safety of zoledronic acid for patients with MGUS and enhanced bone loss...
  26. doi request reprint New drugs in multiple myeloma
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, USA bOncotherapeutics, Los Angeles, California 90069, USA
    Curr Opin Support Palliat Care 2:204-10. 2008
    ..This review will focus on the clinical trials that have reinforced the use of these new agents. Also, we will briefly take a look at the newer drugs making their way out of the laboratory and into early phase studies...
  27. ncbi request reprint Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis
    Hank H Yang
    Institute for Myeloma and Bone Cancer Research, Los Angeles, CA, USA
    J Clin Oncol 21:4239-47. 2003
    ..On the basis of these encouraging results, clinical studies are underway to test the efficacy of PS-341 and chemotherapeutic agents as combination therapy in treating patients with refractory and relapsed MM...
  28. ncbi request reprint A novel angiogenesis model for screening anti-angiogenic compounds: the chorioallantoic membrane/feather bud assay
    Haiming Chen
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA
    Int J Oncol 37:71-9. 2010
    ....
  29. ncbi request reprint A retrospective study to evaluate the work-up and follow-up of patients with monoclonal gammopathy of undetermined significance
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA
    Clin Lymphoma Myeloma Leuk 11:336-41. 2011
    ....
  30. ncbi request reprint Results of a multicenter open-label randomized trial evaluating infusion duration of zoledronic acid in multiple myeloma patients (the ZMAX trial)
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, West Hollywood, California 90069, USA
    J Support Oncol 9:32-40. 2011
    ....
  31. ncbi request reprint Myeloma bone disease and treatment options
    Howard S Yeh
    Hematology Oncology Department, Institute for Myeloma and Bone Cancer Research, 9201W Sunset Blvd, Suite 300, W Hollywood, CA 90069, USA
    Eur J Cancer 42:1554-63. 2006
    ..As our understanding of the pathophysiology of myeloma bone disease continues to increase, new target therapies will continue to emerge offering new and more advanced options for the management of myeloma bone disease...
  32. ncbi request reprint Antitumor effects of bisphosphonates: from the laboratory to the clinic
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, West Hollywood, California, USA
    Curr Opin Support Palliat Care 5:233-40. 2011
    ..The use of bisphosphonates has focused on their antibone resorptive effects but recent studies have shown that these drugs also possess a variety of antitumor effects in the laboratory that are now being observed in clinical trials...
  33. ncbi request reprint LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma
    Richard A Campbell
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA
    Int J Oncol 28:1409-17. 2006
    ..Our new clinically relevant SCID models of human myeloma should greatly facilitate drug development and enable novel therapies to quickly move from the laboratory to the clinic...
  34. doi request reprint Animal models of multiple myeloma and their utility in drug discovery
    Richard A Campbell
    Institute for Myeloma and Bone Cancer Research, West Hollywood, California, USA
    Curr Protoc Pharmacol . 2008
    ..Once these tumors are generated, they can be used to evaluate novel anti-MM agents and other therapies...
  35. doi request reprint Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, West Hollywood, California 90069, USA
    Am J Hematol 86:25-30. 2011
    ..Although ONJ and renal deterioration may infrequently occur with ZOL, most patients do not experience worsening of these conditions with ongoing treatment with this bisphosphonate...
  36. doi request reprint NF-kappaB in the pathogenesis and treatment of multiple myeloma
    Zhi Wei Li
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA
    Curr Opin Hematol 15:391-9. 2008
    ..This review aims to summarize recent advances in the mechanisms through which the activation of the transcription factor NF-kappaB contributes to the pathogenesis of multiple myeloma...
  37. doi request reprint Therapeutic options in the management of myeloma bone disease
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, USA
    Semin Oncol 37:S20-9. 2010
    ..Ongoing studies will help further refine and optimize the timing and duration of BP therapy in patients with myeloma bone disease...
  38. ncbi request reprint Managing bone complications of solid tumors
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, West Hollywood, California, USA
    Cancer Biol Ther 5:1086-9. 2006
    ....
  39. ncbi request reprint Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, USA
    Clin Lymphoma Myeloma 7:192-8. 2006
    ..The activity and tolerability observed in clinical studies promise to make arsenic-based chemotherapy a viable treatment option for patients whose disease does not respond to or who cannot tolerate other chemotherapy regimens...
  40. ncbi request reprint Treatment for myeloma bone disease
    Howard S Yeh
    Institute for Myeloma and Bone Cancer Research, West Hollywood, California 90069, USA
    Clin Cancer Res 12:6279s-6284s. 2006
    ..As our understanding of the pathophysiology of myeloma bone disease continues to grow, new target therapies will continue to emerge, offering new and more advanced options for the management of myeloma bone disease...
  41. ncbi request reprint Treatment strategies for myeloma bone disease
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, UCLA School of Medicine, Los Angeles, California, USA
    Oncology (Williston Park) 17:1678, 1681-2. 2003
  42. ncbi request reprint A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma
    James R Berenson
    Institute for Myeloma and Bone Cancer Research and Oncotherapeutics, Los Angeles, CA, USA
    Clin Lymphoma 5:130-4. 2004
  43. ncbi request reprint Bone complications in multiple myeloma
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, West Hollywood, California, USA
    Cancer Biol Ther 5:1082-5. 2006
    ..us.zometa.com) in reduction of pain, reduction of SREs and survival. Moreover, recent data suggest direct and indirect antimyeloma activity of pamidronate and zoledronic acid...
  44. ncbi request reprint In vivo models of multiple myeloma (MM)
    Eric Sanchez
    Institute for Myeloma and Bone Cancer Research, West Hollywood, California, USA Electronic address
    Biochem Pharmacol 89:313-20. 2014
    ..However, in vivo models have been criticized for having a low clinical predictive power of new chemical entities (NCEs). Despite this, the knowledge gained from in vivo models of MM has without a doubt benefited MM patients. ..
  45. ncbi request reprint Treatment strategies for skeletal complications of cancer
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, West Hollywood, California, USA
    Cancer Biol Ther 5:1074-7. 2006
    ....
  46. ncbi request reprint Pathophysiology of bone metastases
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, West Hollywood, California, USA
    Cancer Biol Ther 5:1078-81. 2006
    ....
  47. pmc Using a powered bone marrow biopsy system results in shorter procedures, causes less residual pain to adult patients, and yields larger specimens
    James R Berenson
    Oncotherapeutics, Inc, 9201 W, Sunset Blvd, W, Hollywood, CA 90069, USA
    Diagn Pathol 6:23. 2011
    ....
  48. ncbi request reprint Monoclonal gammopathy of undetermined significance: a consensus statement
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA
    Br J Haematol 150:28-38. 2010
    ..The following consensus statement outlines the conclusions and marks the first time that a consensus statement for the screening and treatment of MGUS has been clearly stated...
  49. ncbi request reprint Overexpression of Yin Yang 1 in bone marrow-derived human multiple myeloma and its clinical significance
    Sara Huerta-Yepez
    Department of Microbiology, Immunology and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    Int J Oncol 45:1184-92. 2014
    ..These findings highlight the potential prognostic significance of YY1 expression level in MM patients and as a therapeutic target. ..
  50. ncbi request reprint Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status
    Howard S Yeh
    Institute for Myeloma and Bone Cancer Research, 9201 W Sunset Boulevard, West Hollywood, CA 90069, USA
    Br J Haematol 133:526-9. 2006
    ..001). These results suggest that serum PTN may be a new biomarker for monitoring the disease status and therapeutic response of MM patients...
  51. ncbi request reprint Supportive care in myeloma
    James R Berenson
    Institute for Myeloma and Bone Cancer Research, USA
    Clin Adv Hematol Oncol 2:569, 571. 2004
  52. ncbi request reprint Treatment of hypercalcemia of malignancy with bisphosphonates
    James R Berenson
    Division of Hematology Oncology, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Semin Oncol 29:12-8. 2002
    ..Furthermore, zoledronic acid has a safety profile similar to that of pamidronate and other intravenous bisphosphonates. Thus, zoledronic acid represents a significant therapeutic advance in the clinical management of HCM...
  53. doi request reprint Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important
    James R Berenson
    Oncotherapeutics, West Hollywood, CA, USA
    Clin Lymphoma Myeloma 9:311-5. 2009
    ..With proper diagnostic and treatment strategies, these patients will experience improved outcomes and quality of life...
  54. ncbi request reprint A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma
    Hank H Yang
    Department of Medicine, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, California 90084, USA
    Clin Lymphoma 4:119-22. 2003
  55. ncbi request reprint American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma
    James R Berenson
    American Society of Clinical Oncology, Health Services Research Department, Alexandria, VA 22314, USA
    J Clin Oncol 20:3719-36. 2002
    ....
  56. ncbi request reprint Advances in the biology and treatment of myeloma bone disease
    James R Berenson
    Multiple Myeloma and Bone Metastasis Program, Cedars Sinai Medical Center, University of California Las Angeles School of Medicine, 8700 Beverly Boulevard, Bev Mod 1, Room 100, Los Angeles, CA 90402, USA
    Semin Oncol 29:11-6. 2002
    ....
  57. ncbi request reprint Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients
    James R Berenson
    Cedars Sinai Medical Center and the Jonsson Comprehensive Cancer Center, University of California Los Angeles, USA
    Blood 99:3163-8. 2002
    ..Thus, 50 mg, oral, alternate-day prednisone is effective maintenance treatment for multiple myeloma patients who achieve a response to induction chemotherapy. (Blood. 2002;99:3163-3168)..
  58. ncbi request reprint The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents
    Mark H Ma
    Division of Hematology and Oncology, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Clin Cancer Res 9:1136-44. 2003
    ..Thus, these results suggest that inhibition of NF-kappaB with PS-341 may overcome chemoresistance and allow doses of chemotherapeutic agents to be markedly reduced with antitumor effects without significant toxicity...
  59. ncbi request reprint The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review
    Theresa Hahn
    Roswell Park Cancer Institute, Department of Medicine, Buffalo, New York 14263, USA
    Biol Blood Marrow Transplant 9:4-37. 2003
    ..The priority area of needed future research is maintenance therapy posttransplantation with nothing versus interferon alpha versus other agents such as corticosteroids or thalidomide or its derivatives...
  60. ncbi request reprint Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture
    Joseph M Unger
    Southwest Oncology Group Statistical Center and the Puget Sound Oncology Consortium, Seattle, WA, USA
    J Clin Oncol 21:246s-252s. 2003
    ..Meanwhile the prevention of cancer has received less attention...
  61. ncbi request reprint Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma
    Allan Lipton
    Division of Oncology, Penn State University Milton S Hershey Medical Center, Hershey, PA 17033, USA
    Clin Lymphoma Myeloma 7:346-53. 2007
    ..The aim of this review is to improve our understanding of bone markers as a clinical tool for the management of malignant bone disease in patients with MM...
  62. ncbi request reprint Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, 325 West 15th Street, New York, NY, USA
    Haematologica 91:929-34. 2006
    ..BACKGROUND AND OBJECTIVEs: The efficacy and safety of added dexamethasone were assessed in patients with relapsed and/or refractory multiple myeloma who had a suboptimal response to bortezomib alone...
  63. pmc Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma
    Sagar Lonial
    Winship Cancer Institute, Emory University, Atlanta, GA, USA
    Blood 106:3777-84. 2005
    ..The exact mechanism underlying bortezomib-induced thrombocytopenia remains unknown but it is unlikely to be related to marrow injury or decreased thrombopoietin production...
  64. ncbi request reprint Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function
    Sundar Jagannath
    Blood Stem Cell and Bone Marrow Transplantation, St Vincent s Comprehensive Cancer Center, New York, New York 10011 8202, USA
    Cancer 103:1195-200. 2005
    ..Bortezomib is a potent, reversible proteasome inhibitor that has been approved for the treatment of recurrent and/or refractory multiple myeloma, but its activity in patients with renal impairment has not been studied to date...
  65. ncbi request reprint Circulating endothelial progenitor cells in multiple myeloma: implications and significance
    Hong Zhang
    Division of Hematology Oncology, Department of Medicine, SUNY Downstate Medical Center, Box 20, 450 Clarkson Ave, Brooklyn, NY 11203, USA
    Blood 105:3286-94. 2005
    ..The results also highlight the anti-angiogenic properties of thalidomide and CC-5013 and further elucidate possible mechanisms of their effectiveness against MM. (Blood. 2005;105:3286-3294)...
  66. ncbi request reprint Identification of polymorphisms of the IkappaBalpha gene associated with an increased risk of multiple myeloma
    Kimberly M Parker
    Division of Hematology and Oncology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Cancer Genet Cytogenet 137:43-8. 2002
    ..In addition, we detected two polymorphisms in the IkappaBalpha gene that have not been previously reported. Together, these results provide the basis for future evaluation the IkappaBalpha/NF-kappaB pathway in MM patients...
  67. pmc Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference
    Allan Lipton
    Milton S Hershey Medical Center, Penn State University College of Medicine, Hershey, Pennsylvania 17033 0850, USA, and Department of Oncology, Norwegian Radium Hospital, Oslo, Norway
    Clin Cancer Res 12:6209s-6212s. 2006
    ..The conclusions reached during the 2-day meeting are summarized in this article and presented in more detail in the individual articles and accompanying discussion sessions that comprise the conference proceedings...
  68. pmc Comparison of twin and autologous transplants for multiple myeloma
    Asad Bashey
    BMT Group of Georgia, Atlanta, GA, USA
    Biol Blood Marrow Transplant 14:1118-24. 2008
    ..49, 95% confidence interval [CI] 0.28-0.86, P = .011). Twin transplants have a significantly lower relapse risk than autotransplants in MM, suggesting that graft composition may impact outcomes following high-dose chemotherapy...
  69. ncbi request reprint Proteasome inhibitors: closing the garbage can opens up new therapeutic options for patients with B-cell malignancies
    James R Berenson
    Clin Lymphoma Myeloma 7:S182-3. 2007